Point-of-Care Testing Consolidation Continues as Danaher Buys Cepheid

article image

Summer ended with what might be the beginning of a heat wave in diagnostics, as Danaher's pending acquisition of Cepheid, a leader in point-of-care molecular diagnostics testing, shows how right the climate is for M&A.

Danaher Inc.’s $4 billion acquisition of Cepheid Inc., announced just after Labor Day weekend, is the latest in what analysts expect to be a march toward consolidation in the thriving point-of-care (POC) segment of the clinical diagnostics market.


This article is restricted to subscribers only.

Sign in to continue reading.


We're here to help! Please contact us at: